Market Place
Sourcing Support
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
12 Dec 2023 //
BUSINESSWIRE
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
26 Jun 2023 //
GLOBENEWSWIRE
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period
16 Jun 2023 //
BUSINESSWIRE
Ironwood pays $1B for VectivBio and its phase 3 GI drug
23 May 2023 //
FIERCE BIOTECH
Ironwood Enters into Definitive Agreement to Acquire VectivBio
22 May 2023 //
PRESS RELEASE
VectivBio Publishes Invitation to the Annual General Meeting
10 May 2023 //
GLOBENEWSWIRE
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
19 Apr 2023 //
GLOBENEWSWIRE
VectivBio to Report Full Year 2022 Financial Results
12 Apr 2023 //
GLOBENEWSWIRE
VectivBio and Asahi Kasei Pharma Announce the Start of a PI Study of Apraglutide
13 Mar 2023 //
GLOBENEWSWIRE
VectivBio Announces Results of Extraordinary General Meeting
09 Dec 2022 //
GLOBENEWSWIRE
VectivBio Publishes Invitation to the Extraordinary General Meeting Shareholders
16 Nov 2022 //
GLOBENEWSWIRE
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
09 Nov 2022 //
GLOBENEWSWIRE
VectivBio Announces Enrollment for PIII Study Investigating Apraglutide
03 Nov 2022 //
GLOBENEWSWIRE
VectivBio Announces Closing of $125M Underwritten Offering of Ordinary Shares
18 Oct 2022 //
GLOBENEWSWIRE
VectivBio raises $125M ahead of lead program`s big readout
13 Oct 2022 //
ENDPTS
VectivBio Reports +VE Interim Clinical from STARS Nutrition, Ph2 Apraglutide
13 Oct 2022 //
GLOBENEWSWIRE
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
12 Oct 2022 //
GLOBENEWSWIRE
VectivBio Announces Closing of $54 Million Aggregate Financing
29 Jun 2022 //
GLOBENEWSWIRE
VectivBio Announces Launch of Public Offering of Ordinary Shares
14 Jun 2022 //
GLOBENEWSWIRE
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
14 Jun 2022 //
GLOBENEWSWIRE
VectivBio Announces 1st Two Patients Dosed in PII STARGAZE Study of Apraglutide
02 Jun 2022 //
GLOBENEWSWIRE
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
09 May 2022 //
GLOBENEWSWIRE
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
07 Apr 2022 //
GLOBENEWSWIRE
VectivBio Nabs Japan License Deal, Loan Facility Agreement, of up to $117M
30 Mar 2022 //
GLOBENEWSWIRE
VectivBio Presents New Clinical Data Supporting Apraglutide for SBS-IF
29 Mar 2022 //
GLOBENEWSWIRE
VectivBio Presents Preclinical Data Supporting Apraglutide for Acute GvHD
23 Mar 2022 //
GLOBENEWSWIRE
VectivBio Announces Successful Opening of US IND for Apraglutide
20 Oct 2021 //
GLOBENEWSWIRE
VectivBio Gets FDA Clearance for IND of Apraglutide
19 Oct 2021 //
MARKETWATCH
VectivBio Announces Upcoming Investor Events
16 Sep 2021 //
GLOBENEWSWIRE
VectivBio Announces Results of Extraordinary General Meeting
03 Sep 2021 //
GLOBENEWSWIRE
VectivBio to Acquire Comet Therapeutics and Host R&D Day
31 Aug 2021 //
BIO SPACE
VectivBio Grabs Tail Of Comet Therapeutics In New Rare Disease Play
31 Aug 2021 //
SCRIP
VectivBio buys out small Massachusetts biotech, focus on metabolic disease
31 Aug 2021 //
ENDPTS
VectivBio Nominates Paul R. Carter and Murray W. Stewart for Election to its BOD
12 Jul 2021 //
GLOBENEWSWIRE
VectivBio Receives FDA Orphan Drug Designation for Apraglutide
24 Jun 2021 //
GLOBENEWSWIRE
VectivBio Announces 1st Patient Dosed in Metabolic Balance Study of Apraglutide
15 Jun 2021 //
GLOBENEWSWIRE
VectivBio Announces Pricing of Initial Public Offering
09 Apr 2021 //
GLOBENEWSWIRE
VectivBio Announces First Patient Dosed in Pivotal Ph 3 Trial of Apraglutide
03 Feb 2021 //
PRNEWSWIRE
VectivBio Strengthens Business Development Capabilities with Key Appointments
04 Nov 2020 //
PRNEWSWIRE
